15% fall discount applied automatically at checkoutFree USA shipping over $100Free worldwide shipping over $200
Sign in 0

Safety data sheets

Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by PrymaLab Analytical for the catalogue items listed in Section 1.
Download PDF
PrymaLab
PrymaLab AnalyticalSafety data sheet · lyophilized powder, vialPrymaLab LLC · 3705 Music Branch Rd, Ashland, KY 41102
Document number PL-SDS-121 Revision 1.0 · Oct 3, 2026

Oxytocin Lyophilized powder, vial · 1 catalogue item

Danger
  • H301 + H331 Toxic if swallowed or if inhaled.
  • H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
  • H317 May cause an allergic skin reaction.
  • H360 May damage fertility or the unborn child.
  • H413 May cause long lasting harmful effects to aquatic life.
For laboratory research use only. Not for human or veterinary use; not a drug, food, dietary supplement, cosmetic or household product.

1Identification

Product identifierOxytocin — lyophilized powder, vial
Catalogue items coveredOxytocin 2mg PL-OXYTOCIN-2MG-VIAL
Synonyms / chemical namesOxytocin: Oxytocin (acetate salt as supplied) (CAS 50-56-6)
Recommended useLaboratory research chemical for in-vitro and animal-model studies by trained personnel.
Restrictions on useNot for human or veterinary use, diagnosis or therapy. Not for use as a drug, food, dietary supplement, cosmetic or in household products. Not for resale to the public for personal use.
SupplierPrymaLab LLC (PrymaLab Analytical), 3705 Music Branch Rd, Ashland, KY 41102, United States · Tel. +1 (606) 465-9063 · michael@prymalab.net · https://prymalab.net
Emergency telephonePoison Help (US, 24 h): 1-800-222-1222 · Supplier (business hours, US Eastern): +1 (606) 465-9063

2Hazard(s) identification

Classification of the substance

  • Acute toxicity, oral, Category 3 — H301
  • Acute toxicity, inhalation, Category 3 — H331
  • Respiratory sensitisation, Category 1 — H334
  • Skin sensitisation, Category 1 — H317
  • Reproductive toxicity, Category 1A — H360
  • Hazardous to the aquatic environment, long-term, Category 4 — H413

Label elements

GHS06 — Skull and crossbones (acute toxicity)GHS08 — Health hazard

Signal word: Danger

Hazard statements

  • H301 + H331 Toxic if swallowed or if inhaled.
  • H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
  • H317 May cause an allergic skin reaction.
  • H360 May damage fertility or the unborn child.
  • H413 May cause long lasting harmful effects to aquatic life.

Precautionary statements

Prevention

  • P201 Obtain special instructions before use.
  • P202 Do not handle until all safety precautions have been read and understood.
  • P261 Avoid breathing dust, mist or spray.
  • P264 Wash hands and any exposed skin thoroughly after handling.
  • P270 Do not eat, drink or smoke when using this product.
  • P271 Use only outdoors or in a well-ventilated area.
  • P272 Contaminated work clothing should not be allowed out of the workplace.
  • P273 Avoid release to the environment.
  • P280 Wear protective gloves, protective clothing and eye protection.
  • P284 In case of inadequate ventilation wear respiratory protection.

Response

  • P301+P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor.
  • P302+P352 IF ON SKIN: Wash with plenty of water.
  • P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
  • P308+P313 IF exposed or concerned: Get medical advice/attention.
  • P311 Call a POISON CENTER or doctor.
  • P321 Specific treatment: see Section 4 of this safety data sheet.
  • P330 Rinse mouth.
  • P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
  • P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER or doctor.
  • P362+P364 Take off contaminated clothing and wash it before reuse.

Storage

  • P403+P233 Store in a well-ventilated place. Keep container tightly closed.
  • P405 Store locked up.

Disposal

  • P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.

Hazards not otherwise classified / other hazards

  • Pharmacologically active material. Accidental injection, ingestion or absorption may produce systemic effects consistent with the compound's mechanism of action; see Section 11.
  • Finely divided organic powder may form combustible dust concentrations in air if dispersed in bulk (not expected at laboratory scale).

3Composition / information on ingredients

Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap.

IngredientCAS No.FormulaConcentrationQuantityIngredient classification
Oxytocin
Oxytocin (acetate salt as supplied)		50-56-6C43H66N12O12S2≥ 95% (dry basis, as supplied)2 mg per vialAcute tox. oral 3 · H301 Acute tox. inhalation 3 · H331 Resp. sens. 1 · H334 Skin sens. 1 · H317 Repr. 1A · H360 Aquatic chronic 4 · H413

Peptides are supplied as the acetate or trifluoroacetate salt unless stated otherwise; the counter-ion and residual water make up the balance of a lyophilized product. Concentration limits used for mixture classification follow OSHA HCS 2012 Appendix A.

4First-aid measures

GeneralIf exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.
InhalationMove the person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER or doctor. If experiencing respiratory symptoms (wheezing, shortness of breath), call a POISON CENTER or doctor.
Skin contactTake off contaminated clothing and wash it before reuse. Wash the skin with plenty of soap and water. If a rash develops, get medical advice: the material may cause an allergic skin reaction.
Eye contactRinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
IngestionRinse mouth. Do not induce vomiting. Immediately call a POISON CENTER or doctor.
Most important symptoms and effectsAllergic skin rash; wheezing, chest tightness or asthma-like symptoms after inhalation in sensitised individuals; nausea, vomiting and other systemic effects after ingestion.
Indication of immediate medical attentionTreat symptomatically. Show this safety data sheet to the attending physician. No specific antidote is known; monitor for the effects described in Section 11.

5Fire-fighting measures

Suitable extinguishing mediaWater spray, carbon dioxide, dry chemical or alcohol-resistant foam. Use measures appropriate to the surrounding fire.
Unsuitable extinguishing mediaNone known. Do not use a high-pressure water jet on powders (dust dispersion).
Specific hazardsCombustible organic solid; finely divided powder may form dust clouds. Not flammable in the quantities supplied. Thermal decomposition may release carbon monoxide, carbon dioxide and nitrogen oxides, and sulfur oxides.
Protective equipment for fire-fightersSelf-contained breathing apparatus and full protective clothing. Prevent run-off from entering drains.

6Accidental release measures

Personal precautionsWear the protective equipment in Section 8. Keep unprotected people away. Avoid dust formation and inhalation of dust.
Environmental precautionsDo not allow material to reach drains, surface water or soil. Quantities supplied are small; collect for disposal.
Methods for cleaning upAvoid dust formation. Dampen spilled powder with water, wipe up with absorbent material, place in a sealed container for disposal and clean the area with water and detergent. Decontaminate surfaces with 70% alcohol or detergent and water.

7Handling and storage

Precautions for safe handlingOpen vials only in a clean area. Avoid generating or inhaling dust; weigh or reconstitute inside a ventilated enclosure when the full contents are handled as a dry powder. Reconstitute by adding diluent slowly to the vial wall; do not shake. Wash hands after handling. Do not eat, drink or smoke in the handling area. Follow the precautionary statements in Section 2.
Conditions for safe storageStore the sealed vial at the temperature stated in Section 9 (typically −20 °C for peptides, 2–8 °C for proteins), desiccated and protected from light. Allow the vial to reach room temperature before opening to avoid condensation. Reconstituted solutions: 2–8 °C, protected from light; use within the period established by your laboratory. Keep the container tightly closed and labelled, out of reach of unauthorised persons (store locked up).
Storage temperature−20 °C (sealed vial), desiccated and protected from light; 2–8 °C acceptable for short periods
Incompatible materialsStrong oxidising agents, strong acids and bases; reducing agents (disulfide bond).

8Exposure controls / personal protection

Occupational exposure limitsNo occupational exposure limits (OSHA PEL, ACGIH TLV, NIOSH REL) have been established for any ingredient.
Engineering controlsGood general laboratory ventilation. Weigh or manipulate dry powder in a ventilated enclosure (powder hood, biosafety cabinet or fume hood). An eyewash station should be available.
Eye / face protectionSafety glasses with side shields (ANSI Z87.1 / EN 166).
Skin protectionNitrile gloves (inspect before use; change after contamination) and a laboratory coat.
Respiratory protectionNot normally required with the engineering controls above. Where dust cannot be controlled, use a NIOSH-approved N95 (or P2) particulate respirator.
Hygiene measuresWash hands after handling and before breaks. Remove contaminated clothing. Do not pipette by mouth.

9Physical and chemical properties

Physical state / appearanceSolid. White to off-white lyophilized powder.
Odour / odour thresholdCharacteristic (Cayman)
pHNot applicable (solid); aqueous solutions typically pH 4–7
Melting / freezing point200-204 C with decomposition (ChemicalBook); Cayman: undetermined
Boiling pointNot determined (decomposes)
Flash point / flammabilityNot applicable (non-flammable solid); combustible organic material
Vapour pressure / densityNegligible (solid)
Relative densityNo data available (bulk density of lyophilized cake is low)
SolubilityWater: 10 mg/mL, clear, colorless (Sigma O6379 acetate salt hydrate); soluble to 1 mg/mL in water (Tocris); ChemicalBook: slightly soluble in water and methanol (free peptide); soluble in dilute aceti.
Partition coefficient (log Pow)No data available
Auto-ignition / decomposition temperatureNo data available; peptides decompose above about 200 °C
Molecular formula / massOxytocin: C43H66N12O12S2, 1007.2 g/mol
Other informationFree peptide C43H66N12O12S2, MW 1007.2, CAS 50-56-6; monoacetate salt CAS 6233-83-6; Sigma storage class 11 (combustible solids), WGK 3; Cayman: not flammable, no explosion hazard; store 2-8 C (Sigma).

10Stability and reactivity

ReactivityNo hazardous reactivity under normal laboratory conditions.
Chemical stabilityStable when stored as recommended (Section 7). Lyophilized peptides are hygroscopic and degrade faster once moist or reconstituted.
Possibility of hazardous reactionsNone known.
Conditions to avoidHeat, direct light, moisture, repeated freeze–thaw cycles.
Incompatible materialsStrong oxidising agents, strong acids and bases; reducing agents.
Hazardous decomposition productsCarbon oxides and nitrogen oxides, sulfur oxides on combustion. No hazardous decomposition under recommended storage.

11Toxicological information

Likely routes of exposure: Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.

Symptoms related to the physical, chemical and toxicological characteristics: Allergic skin rash; wheezing, chest tightness or asthma-like symptoms after inhalation in sensitised individuals; nausea, vomiting and other systemic effects after ingestion.

Oxytocin Oxytocin (acetate salt as supplied) · CAS 50-56-6

Substance classification adopted: Acute tox. oral 3 · H301 Acute tox. inhalation 3 · H331 Resp. sens. 1 · H334 Skin sens. 1 · H317 Repr. 1A · H360 Aquatic chronic 4 · H413
Cayman Chemical SDS (oxytocin acetate, rev. 2026), the most conservative internally consistent set. Merck Animal Health reports LD50 oral rat > 21 mg/kg and intravenous rat 2.3 mg/kg.

Acute toxicity, oralLD50 oral rat > 21 mg/kg (Merck AH; ChemicalBook quotes > 20,520 ug/kg); LD50 oral mouse > 514 mg/kg (Merck AH); Bimeda uses ATE oral 100 mg/kg (Category 3). Cayman: no value given; classifies Acute Tox. 3 oral/inhalation
Acute toxicity, dermalNo data available
Acute toxicity, inhalationNo data available (Cayman classifies Category 3 by analogy with oral)
Skin corrosion/irritationNo irritant effect (Cayman); not classified
Serious eye damage/irritationNo irritating effect (Cayman); not classified
Respiratory or skin sensitisationCayman: sensitisation possible through inhalation and through skin contact (Resp. Sens. 1 H334; Skin Sens. 1 H317). Merck AH/Bimeda: not classified for sensitisation
Germ cell mutagenicityNot classified; no data (Merck AH)
CarcinogenicityNot listed by IARC, NTP or OSHA
Reproductive toxicityCayman: Repr. 1A H360; Bimeda: Repr. 1B; Merck AH: 'may damage the unborn child'; ChemicalBook: Repr. 2 H361. Uterotonic hormone - induces labour, uterine contraction, fetal distress, risk of abortion
STOT, single exposureNo data available; human overdose effects: water intoxication/hyponatraemia, hypotension, cardiac arrhythmia, nausea, vomiting (Merck AH)
STOT, repeated exposureNo data available
Aspiration hazardNo data available
  • Uterotonic hormone; may cause uterine contractions. Also classified Repr. 1B by Bimeda and Repr. 2 by ChemicalBook.

Carcinogen listings: no ingredient is listed as a carcinogen by IARC, NTP or OSHA.

12Ecological information

Oxytocin: Cayman: water hazard class 2 (self-assessment): hazardous for water; classified Aquatic Chronic 4 (H413). Merck AH: 'toxic effects cannot be excluded' for acute and chronic aquatic toxicity; no measured data. Peptide - expected biodegradable.

Persistence and degradability: peptides and amino acids are expected to biodegrade readily; benzyl alcohol is readily biodegradable (92–96% in 14 days, OECD 301C). Bioaccumulative potential: low (hydrophilic, log Pow < 3 where known). Mobility in soil: water-soluble; mobile. PBT/vPvB: not expected to meet the criteria. Other adverse effects: none known. Do not release concentrated material to the environment.

13Disposal considerations

Dispose of unused material and contaminated packaging through a licensed chemical-waste contractor in accordance with federal (40 CFR 261), state and local regulations; the material is not a listed RCRA hazardous waste but is classified as hazardous for supply and should be managed as chemical waste. Do not pour down the drain. Small residues may be inactivated with 10% bleach for 30 minutes before disposal where local rules allow. Empty glass vials and cartridges: remove labels or deface them before recycling or disposal.

14Transport information

UN numberUN 2811
UN proper shipping nameTOXIC SOLID, ORGANIC, N.O.S. (contains Oxytocin)
Transport hazard class6.1
Packing groupIII
Environmental hazardsNot a marine pollutant.
Special precautionsThe quantities supplied (milligram amounts per inner packaging) qualify for the excepted-quantity provisions of 49 CFR 173.4a, IATA DGR 2.6 (code E1) and IMDG 3.5 when packed accordingly. Not a marine pollutant.

15Regulatory information

OSHA Hazard Communication Standard (29 CFR 1910.1200)Hazardous: Acute toxicity, oral (Category 3); Acute toxicity, inhalation (Category 3); Respiratory sensitisation (Category 1); Skin sensitisation (Category 1); Reproductive toxicity (Category 1A); Hazardous to the aquatic environment, long-term (Category 4).
TSCA (Toxic Substances Control Act)Oxytocin: not listed on the TSCA Inventory (supplied for research and development; 40 CFR 720.36).
SARA Title III (Sections 302, 311/312, 313), CERCLANo ingredient is listed as an extremely hazardous substance (Section 302), a Section 313 toxic chemical or a CERCLA hazardous substance. Section 311/312 hazard categories follow the classification in Section 2.
California Proposition 65No ingredient is listed as known to the State of California to cause cancer or reproductive toxicity.
State right-to-know listsNo ingredient is listed.
US FDAThe active substance is also the active ingredient of an approved drug product (oxytocin injection); the material described here is not that approved product, has not been manufactured under cGMP for human use and is sold for laboratory research use only.
US DEA controlled substancesNo ingredient is scheduled under the Controlled Substances Act at the revision date.
InternationalThe classification in Section 2 applies equally under EU CLP (Regulation (EC) 1272/2008) and other UN GHS implementations; peptides of this kind are generally not registered under REACH (research and development use).

16Other information

RevisionRevision 1.0, October 3, 2026 — first issue. Prepared by PrymaLab Analytical, PrymaLab LLC.
Classification methodSubstance classification adopted from the supplier safety data sheets listed below, with the PrymaLab policy adjustments stated in Section 11. Policy: Cayman Chemical is the primary reference for research peptides and novel small molecules and Sigma-Aldrich/Merck for commodity chemicals; a more conservative manufacturer or ECHA classification is adopted where internally consistent; SARMs, GLP-1 receptor agonists, GnRH analogues and gonadotropins carry reproductive-toxicity classifications by expert judgement.
Sources consultedCayman Chemical; ChemicalBook MSDS; Merck Animal Health; Bimeda.
AbbreviationsATE acute toxicity estimate · CAS Chemical Abstracts Service · GHS Globally Harmonized System · HCS Hazard Communication Standard · IARC International Agency for Research on Cancer · LD50/LC50 median lethal dose/concentration · NTP National Toxicology Program · OEL occupational exposure limit · PEL permissible exposure limit · STOT specific target organ toxicity · TLV threshold limit value · WADA World Anti-Doping Agency.

Download the PDF All safety data sheets View the product

RealReviews.io Rate your experience with PrymaLab